Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Active, not recruiting · NCT04373031 · Registry updated 2026-04-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-04-24 | NCT04373031 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Brooklyn ImmunoTherapeutics, LLC | 2 |
| Merck Sharp & Dohme LLC | 650 |
| Providence Health & Services | 35 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Providence Portland Medical Center | Portland | United States | 324 |